Prospects for obesity treatment: MCH receptor antagonists.
The convergence of the orphan G protein-coupled receptor SLC-1 with its orexigenic neuropeptide ligand melanin-concentrating hormone (MCH) in 1999 stimulated considerable research activity aimed at characterizing the role of this receptor system in the regulation of body weight. A solid body of genetic and pharmacological evidence now supports a role for MCH in the modulation of food intake and energy expenditure. High-throughput screening efforts have led to the identification of small molecule MCH receptor antagonists with diverse structural features and drug-like properties. In vivo results with two of these antagonists indicate efficacy in several animal models of body weight regulation and feeding behavior. Based on these preclinical findings, it is likely that reports from clinical studies of MCH antagonists will soon be forthcoming.
Collins
Christine A
CA
Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA.
Kym
Philip R
PR
D000595:Amino Acid Sequence; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001835:Body Weight / Q000502:physiology; D006801:Humans; D007028:Hypothalamic Hormones / Q000037:antagonists & inhibitors* / Q000502:physiology; D008543:Melanins / Q000037:antagonists & inhibitors* / Q000502:physiology; D008969:Molecular Sequence Data; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology; D010907:Pituitary Hormones / Q000037:antagonists & inhibitors* / Q000502:physiology
D019440:Anti-Obesity Agents; D007028:Hypothalamic Hormones; D008543:Melanins; D010907:Pituitary Hormones; C019463:melanin-concentrating hormone